NCT06924281

Team Science (The Liver Health Study)

Completed NA Results posted Last updated 4 February 2026

What this trial tests

NA trial testing Brief motivational interviewing with personalized feedback in Steatotic Liver Disease of Mixed Origin (MetALD) in 14 participants. Completed in 31 August 2025.

Timeline

25 April 2025

Primary endpoint
29 August 2025

31 August 2025

Quick facts

Lead sponsor	Brown University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	14
Start date	25 April 2025
Primary completion	29 August 2025
Estimated completion	31 August 2025
Sites	1 location across United States

Drugs / interventions tested

• Brief motivational interviewing with personalized feedback
• Brief motivational interviewing with standard health information

Conditions studied

• Steatotic Liver Disease of Mixed Origin (MetALD) — all drugs for Steatotic Liver Disease of Mixed Origin (MetALD) →

Sponsor

Brown University

Who can join

21 and older, any sex, with Steatotic Liver Disease of Mixed Origin (MetALD). Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Proportion Screened With Alcohol Intake and Weight-related Risks for Metabolism and Alcohol-associated Liver Disease Primary · Screening

The primary feasibility outcome is the proportion screened who have alcohol intake and weight-related risks for metabolism and alcohol-associated liver disease. Alcohol intake risk is identified by the 3-item Alcohol Use Disorder Identification Test-Consumption subscale (AUDIT-C). Weight-related risk is identified by body mass index, calculated from weight and height.

Group	Value	95% CI
Pre-randomization Screening Phase	26

Proportion Eligible and Invited to Participate Who Agree to Noninvasive Liver Imaging With Fibroscan® and Arrive for Scheduled Baseline Appointment Primary · Baseline

Group	Value	95% CI
Pre-randomization Screening Phase	14

Satisfaction With Fibroscan® Liver Imaging Primary · Baseline

Satisfaction with liver screening is assessed with a single-item visual analog scale with 0 indicating low satisfaction and 100 indicating high satisfaction.

Group	Value	95% CI
Standard Intervention	88.5	± 11.2
Enhanced Intervention	93.9	± 7.1

Sponsor's own description

Liver damage from alcohol intake and weight-related behaviors is preventable and treatable only through lifestyle changes. This mixed-methods randomized controlled trial compares standard and enhanced approaches to screening, brief intervention, and referral to treatment/prevention (SBIRT/P) to identify and intervene for metabolism- and alcohol-associated liver disease (MetALD). Our multidisciplinary team aims to show that integrating results of noninvasive liver screening with Fibroscan®, a painless ultrasound that measures stiffness and fat in the liver, can optimize our brief intervention. The study population is adults age 21+ who speak Spanish or English from underresourced communities with alcohol- and weight-related risks for MetALD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Addressing Chronic Steatotic Liver Disease through Community Partnerships, Integrated Behavioral Interventions, and Point-of-Care Diagnostics.
   Treloar Padovano H, Monnig MA, De Leon A, Promrat K, et al · · 2026 · PMID 41886659